LEADER 05401nam 2200697Ia 450 001 9910782612503321 005 20200520144314.0 010 $a1-282-11217-1 010 $a9786612112171 010 $a0-470-09254-8 010 $a0-470-09256-4 035 $a(CKB)1000000000719678 035 $a(EBL)427919 035 $a(OCoLC)476271499 035 $a(SSID)ssj0000357543 035 $a(PQKBManifestationID)11278559 035 $a(PQKBTitleCode)TC0000357543 035 $a(PQKBWorkID)10353407 035 $a(PQKB)10594426 035 $a(MiAaPQ)EBC427919 035 $a(Au-PeEL)EBL427919 035 $a(CaPaEBR)ebr10303739 035 $a(CaONFJC)MIL211217 035 $a(MiAaPQ)EBC7147323 035 $a(Au-PeEL)EBL7147323 035 $a(EXLCZ)991000000000719678 100 $a20081201d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCancer chemotherapy$b[electronic resource] /$fRachel Airley 205 $a1st ed. 210 $aChichester, West Sussex ;$aHoboken, NJ $cJ. Wiley$d2009 215 $a1 online resource (362 p.) 300 $aDescription based upon print version of record. 311 $a0-470-09257-2 311 $a0-470-09255-6 320 $aIncludes bibliographical references and index. 327 $aCancer Chemotherapy; Contents; Preface; 1 Cancer epidemiology; 1.1 Cancer incidence, prevalence and mortality; 1.2 Childhood cancers; 1.3 Global epidemiology; 2 Histopathology of cancer; 2.1 Introduction; 2.2 Malignant, benign and normal (non-malignant) tissue; 2.3 Cell death; 3 Carcinogenesis, malignant transformation and progression; 3.1 Introduction; 3.2 Chemical carcinogenesis; 4 Molecular biology of cancer: oncogenes and tumour suppressor genes; 4.1 Introduction; 4.2 Oncogenesis; 4.3 Tumour suppressor genes; 5 Tumour metastasis: a convergence of many theories; 5.1 Introduction 327 $a5.2 Detachment and migration from the primary tumour5.3 Intravasation; 5.4 Transport; 5.5 Extravasation; 5.6 Growth of the metastatic tumour mass; 6 Health professionals in the treatment of cancer; 6.1 Introduction; 6.2 Pathology; 6.3 Radiology; 6.4 Role of the surgical oncologist; 6.5 Oncology pharmacy; 6.6 Oncology nursing; 6.7 The NHS Cancer Plan; 7 Principles of cancer chemotherapy; 7.1 Introduction; 7.2 Timing of chemotherapy; 7.3 Biomarkers and their uses; 7.4 Clinical assessment of biomarkers; 7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy 327 $a8 Classical anticancer agents8.1 Introduction; 8.2 Alkylating agents; 8.3 Antimetabolites; 8.4 Agents derived from natural or semisynthetic products; 8.5 Hormonal anticancer agents; 8.6 Clinically used chemotherapy regimens; 9 The philosophy of cancer research; 9.1 Introduction; 9.2 Structure of cancer research organizations in the United Kingdom; 9.3 Cancer research in the United States; 10 Novel anticancer agents; 10.1 Introduction; 10.2 Target validation; 10.3 Identification and optimization of lead drugs; 10.4 Preclinical pharmacology; 11 Clinical trials; 11.1 Introduction 327 $a11.2 Evaluation of treatment response11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology; 12 Tumour hypoxia; 12.1 Introduction; 12.2 Bioreductive drugs; 12.3 Inhibitors of HIF-1 and HIF-1-regulated genes; 13 Antiangiogenic and antivascular agents; 13.1 History of angiogenesis as a therapeutic target; 13.2 Anti-angiogenic drug targets; 13.3 The return of thalidomide; 13.4 Monoclonal antibodies as anti-angiogenic agents; 13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs; 13.6 Vascular disrupting agents; 14 Tyrosine kinase inhibitors 327 $a14.1 Introduction14.2 Tyrosine kinase inhibitors targeting angiogenesis; 14.3 Non-receptor tyrosine kinase inhibitors; 15 Ras inhibitors; 16 Inhibitors of the Akt/PKB pathway; 17 Targeting stress proteins: HSP90 inhibitors; 18 The proteasome; 18.1 Introduction; 18.2 The proteasome as a target for novel drug strategies; 18.3 Ubiquitylation as a target; 19 Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR); 19.1 Mammalian target of rapamycin; 19.2 Structure and activation of mTOR; 19.3 Novel anticancer agents targeting mTOR; 20 Telomerase 327 $a21 Histone deacetylase: an epigenetic drug target 330 $aThis textbook is a clear and accessible introduction to the scientific and clinical aspects of the creation, development and administration of drugs or drug regimens used in the treatment of cancer. Unique in its approach, this book enables the student to gain an understanding of the pathological, physiological and molecular processes governing malignancy, whilst also introducing the role of health professionals and scientists in the research and treatment of cancer. The book consolidates all the essential information necessary for a full understanding of cancer chemotherapy, providing an info 606 $aCancer$xChemotherapy 606 $aChemotherapy 615 0$aCancer$xChemotherapy. 615 0$aChemotherapy. 676 $a616.99/4061 676 $a616.994061 700 $aAirley$b Rachel$01573380 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910782612503321 996 $aCancer chemotherapy$93849076 997 $aUNINA